Piramal Pharma To Invest $90 Million In Facility Expansions In The US

Piramal Pharma Ltd. on Monday announced plans to invest $90 million to expand two of its existing facilities in the US-Kentucky and Michigan. The investment will be funded through bank loans and internal accruals, the company said in an exchange filing.

The expansion of the Kentucky facility, which specialises in sterile compounding, liquid filling, and lyophilisation for sterile injectable drug products, will include 24,000 square feet of manufacturing space and a new laboratory. This will enable the commercial-scale manufacturing of injectable drug products, facilitating more efficient scale-up for clients. 

Additional upgrades at the facility will feature a new filling line, two commercial-size lyophilisers, a special capping machine, and an external vial washer. The Kentucky expansion is expected to be completed by late 2027.

Meanwhile, the Michigan facility, which focuses on the development and manufacturing of active pharmaceutical ingredients and high-potency active pharmaceutical ingredients, will see the addition of a commercial-scale suite for the development and manufacturing of payload-linkers. The new payload linker suite is expected to be operational before the end of 2025.

These expansions are a response to growing demand from US customers, supporting the trend of onshoring drug supply to the US. Piramal Pharma expects these expansions to create greater opportunities for integrated antibody-drug conjugate projects.